共 50 条
- [1] A first-in-human phase 1 study of LY3410738, a covalent inhibitor of mutant IDH, in advanced myeloid malignanciesCANCER RESEARCH, 2023, 83 (08)DiNardo, Courtney D.Montesinos, PauBenajiba, LinaTriguero, AnaRecher, ChristianSchuh, Andre C.Heiblig, MaelBajel, AshishPigneux, ArnaudAlonso-Domiguez, Juan M.Fathi, Amir T.Grove, CarolynHou, Hsin-AnHeuser, MichaelAssouline, SaritFleming, ShaunShin, Dong-YeopSweet, KendraOdenike, OlatoyosiAltman, JessicaOoi, Melissa Gaik MingLao ZhentangVey, NobertZeidner, JoshuaSalhotra, AmandeepWang, EuniceSchiller, GaryPorkka, KimmoZuckerman, TsilaHavelange, ViolaineJonas, Brian A.Narayanan, SujaathaJang, Jun HoLee, Je-HwanSzpurka, Anna M.Heirich, DanaChen, Hsiao RongHanft, VioletZhao, JunjieGueorguieva, IvelinaZhang, YinStein, Eytan M.
- [2] A phase I study of LY3410738, a first-in-class covalent inhibitor of mutant IDH1 in cholangiocarcinoma and other advanced solid tumors.JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (03)Pauff, James MichaelPapadopoulos, Kyriakos P.Janku, FilipTurk, Anita AhmedGoyal, LipikaShroff, Rachna T.Shimizu, ToshioIkeda, MasafumiAzad, Nilofer SabaCleary, James M.Peters, Mary Linton BounetheauBorad, Mitesh J.Jaeckle, Kurt A.Kizilbash, Sani HaiderTupper, RebeccaFurin, Carrie E.Hanley, Matthew P.Hill, Elizabeth GoodwinXu XiaojianHarding, James J.
- [3] A first-in-human phase 1 study of LY3410738, a covalent inhibitor of mutant IDH, in advanced IDH-mutant cholangiocarcinoma and other solid tumorsCANCER RESEARCH, 2023, 83 (08)Rodon, JordiGoyal, LipikaMercade, Teresa MacarullaIkeda, MasafumiKondo, ShunsukeOh, Do-YounBai, Li-YuanUeno, MakotoItaliano, AntoinePapadopoulos, KyriakosSpigel, DavidKizilbash, Sani H.Cosman, RashaPark, Joon OhChen, Li-TzongYokota, TomoyaTurk, Anita A.Liao, Chih-YiShroff, RachnaEl-Khoueiry, AnthonySatoh, TarohHollebecque, AntoineBorad, Mitesh J.Azad, NiloferJaeckle, Kurt A.Loong, Herbert H.Adeva, JorgeYong, Wei PengZhao, JunjieLiu, HuiSzpurka, Anna M.Gueorguieva, IvelinaPradhan, Kamnesh R.Xu, XiaojianHarding, James J.
- [4] A first-in-human phase 1 study of LY3410738, a covalent inhibitor of mutant IDH1 and IDH2, as monotherapy and in combination with cisplatin and gemcitabine in advanced IDH-mutant cholangiocarcinomaANNALS OF ONCOLOGY, 2023, 34 : S161 - S161Harding, J.Ikeda, M.Goyal, L.Rodon, J.Bai, L.Oh, D.Park, J.Chen, L.Ueno, M.Liao, C.Kondo, S.Cosman, R.Yokota, T.Shroff, R.Satoh, T.Palmieri, L.Hollebecque, A.Adeva, J.Bender, M.Liu, H.Macarulla, T.
- [5] Identification and characterization of LY3410738, a novel covalent inhibitor of cancer-associated mutant Isocitrate Dehydrogenase 1 (IDH1)CANCER RESEARCH, 2019, 79 (13)Brooks, NathanDeWalt, RobinBoulet, SergeLu, ZhaoHaiKays, LisaCavitt, RachelGomez, SandraStrelow, JohnMilligan, PaulRoth, KennethBauer, RenatoAntonysamy, StephenHahn, PatricRankovic, ZoranMcCann, DenisMo, GaryTiu, RamonBurkholder, TimothyGeeganage, SandaruwanGilmour, Raymond
- [6] CLINICAL SAFETY AND ACTIVITY OF AG-120, A FIRST-IN-CLASS, POTENT INHIBITOR OF THE IDH1 MUTANT PROTEIN, IN A PHASE 1 STUDY OF PATIENTS WITH ADVANCED IDH1-MUTANT HEMATOLOGIC MALIGNANCIESHAEMATOLOGICA, 2015, 100 : 214 - 215de Botton, S.Pollyea, D. A.Stein, E. M.DiNardo, C.Fathi, A. T.Roboz, G. J.Collins, R.Swords, R. T.Flinn, I.Altman, J. K.Tallman, M. S.Kantarjian, H.Colby, K.Fan, B.Goldwasser, M.Prahl, M.Agresta, S.Stone, R. M.
- [7] LY3410738, a novel inhibitor of mutant IDH1 is more effective than Ivosidenib and potentiates antileukemic activity of standard chemotherapy in preclinical models of acute myeloid leukemia (AML)CANCER RESEARCH, 2020, 80 (16)Salama, VivianBrooks, NathanSkwarska, AnnaKays, LisaMilligan, PaulNewell, KatherineRoth, KennethGeeganage, SandaruwanGilmour, RaymondChan, Steven M.Sarry, Jean-EmmanuelSabatier, MaryDiNardo, CourtneyKonopleva, Marina
- [8] Discovery of AG-120 (Ivosidenib): A First-in-Class Mutant IDH1 Inhibitor for the Treatment of IDH1 Mutant CancersACS MEDICINAL CHEMISTRY LETTERS, 2018, 9 (04): : 300 - 305Popovici-Muller, JanetaLemieux, Rene M.Artin, ErinSaunders, Jeffrey O.Salituro, Francesco G.Travins, JeremyCianchetta, GiovanniCai, ZhenweiZhou, DingCui, DaweiChen, PingStraley, KimberlyTobin, EricaWang, FangDavid, Muriel D.Penard-Lacronique, VirginieQuivoron, CyrilSaada, VeroniqueDe Botton, StephaneGross, StefanDang, LennyYang, HuaUtley, LukeChen, YueKim, HyeryunJin, ShengfangGu, ZhiweiYao, GuiLuo, ZhiyongLv, XiaobingFang, ChengYan, LipingOlaharski, AndrewSilverman, LeeBiller, ScottSu, Shin-San M.Yen, Katharine
- [9] Clinical safety and activity in a phase I trial of AG-120, a first in class, selective, potent inhibitor of the IDH1-mutant protein, in patients with IDH1 mutant positive advanced hematologic malignanciesEUROPEAN JOURNAL OF CANCER, 2014, 50 : 195 - 195Pollyea, D. A.de Botton, S.Fathi, A. T.Stein, E. M.Tallman, M. S.Agresta, S.Bowden, C.Fan, B.Prah, M.Yang, H.Yen, K.Stone, R. M.
- [10] AG-221, AN ORAL, SELECTIVE, FIRST-IN-CLASS, POTENT INHIBITOR OF THE IDH2 MUTANT ENZYME, INDUCED DURABLE RESPONSES IN A PHASE 1 STUDY OF IDH2 MUTATION-POSITIVE ADVANCED HEMATOLOGIC MALIGNANCIESHAEMATOLOGICA, 2015, 100 : 216 - 217DiNardo, C.Stein, E. M.Altman, J. K.Collins, R.DeAngelo, D. J.Fathi, A. T.Flinn, I.Frankel, A.Levine, R. L.Medeiros, B. C.Patel, M.Pollyea, D. A.Roboz, G. J.Stone, R. M.Swords, R. T.Tallman, M. S.Almon, C.Fan, B.Goldwasser, M.Yen, K.Attar, E.de Botton, S.